Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost monotherapy in Chinese patients with primary open-angle glaucoma or ocular hypertension
ChiCTR-OIC-17011980Phase 4Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Mean intraocular pressure change at month 3 in each subgroup. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on ChiCTR-OIC-17011980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011980.